Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
    Meeting Abstract

    Saura Manich, C.; Modi, S.; Krop, I.; Park, Y. H.; Kim, S. B.; Tamura, K.; André, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+ / human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC)
    Meeting Abstract

    Chandarlapaty, S.; Linden, H. M.; Neven, P.; Petrakova, K.; Bardia, A.; Kabos, P.; Braga, S.; Boni, V.; Pelekanou, V.; Ternès, N.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+ / human epidermal growth factor receptor 2-negative (HER2-) PIK3CA-mutated advanced breast cancer
    Meeting Abstract

    Campone, M.; Bardia, A.; Kabos, P.; Chandarlapaty, S.; Neven, P.; Boni, V.; Lord, S.; Cartot-Cotton, S.; Celanovic, M.; Gosselin, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC)
    Meeting Abstract

    O'Shaughnessy, J.; Brufsky, A.; Rugo, H. S.; Tolaney, S. M.; Diab, S.; Punie, K.; Sardesai, S.; Hamilton, E.; Loirat, D.; Traina, T. A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer
    Meeting Abstract

    Tsai, M.; Han, H. S.; Montero, A. J.; Tkaczuk, K. H.; Assad, H.; Pusztai, L.; Hurvitz, S. A.; Wilks, S. T.; Specht, J. M.; Nanda, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone in 55 patients with relapsed/refractory multiple myeloma with extramedullary disease-subgroup analysis
    Meeting Abstract

    Richardson, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)
    Meeting Abstract

    Swain, S. M.; Tan, A.; Gianni, L.; Kümmel, S.; Dang, C.; Schneeweiss, A.; O'Shaughnessy, J.; Liu, H.; Aguila, C.; Heeson, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A patient-level data meta-analysis of the abscopal effect
    Meeting Abstract

    Hatten, S.; Lehrer, E.; Liao, J.; Sha, M.; Trifiletti, D.; Siva, S.; McBride, S.; Palma, D.; Holder, S.; Zaorsky, N.
    American Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Improved accuracy in predicting survival when supplementing a predictive model with clinical intuition
    Meeting Abstract

    Kao, J.; Zucker, A.; Urso, M.; Karwowski, P.; Bustamante, G.; Lugo, D.; Rowland, L.
    American Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma exposed and/or refractory to prior alkylators - A pooled analysis of the O-12-M1 and HORIZON studies
    Meeting Abstract

    Rodriguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Blade, J.; Cavo, M.; Leleu, X.; Nadeem, O.; Hiemenz, J.; Hassoun, H.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save